Akeso's B7-H3 ADC AK157D1 Cleared for Phase I Trial in Solid Tumours, Expanding HK Biotech Pipeline

🇭🇰 Hong Kong Markets
1

Akeso’s B7-H3 ADC AK157D1 Cleared for Phase I Trial in Solid Tumours, Expanding HK Biotech Pipeline

Akeso (9926.HK) received clearance for its AK157D1 B7-H3 antibody-drug conjugate to begin Phase I trials.

Key points

  • Akeso (9926.HK) received clearance for its AK157D1 B7-H3 antibody-drug conjugate to begin Phase I trials.
  • AK157D1 targets solid tumours using next-generation ADC technology, representing a third differentiated clinical asset.
  • The Phase I clearance advances Akeso’s position as a leading China-based biotech with growing oncology pipeline depth.

:chart_with_upwards_trend: What’s your take on this? Join the discussion below.

Read the full analysis on market.news

🇭🇰 Hong Kong Stocks Regulatory biotech pharma healthcare asia china